Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.59 |
| ▸ | SQLE | Q14534 | 5/20 | 0.45 |
| ▸ | FNTA | P49354 | 1/20 | 0.43 |
| ▸ | FNTB | P49356 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL238726 | 0.92 | ALOX15 (0.46) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL10337451 | 0.92 | ALOX15 (0.46) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL238725 | 0.92 | ALOX15 (0.46) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL10839164 | 0.87 | ALOX15 (0.57) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL10839159 | 0.87 | ALOX15 (0.57) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL6315751 | 0.87 | NR1I2 (0.46) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL18387400 | 0.85 | FNTA (0.43) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| Farnesol SCHEMBL137180 | 0.79 | KMT2A (0.95) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL7882582 | 0.78 | KMT2A (0.55) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL11647482 | 0.78 | KMT2A (0.55) | KMT2AMAPTMEN1CYP3A4ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10398632-B2 | Capsule composition | GIVAUDAN S.A. (CH) | 2019-09-03 | — | — | US | disclosed |
| US-20170312193-A1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | GIVAUDAN S.A. (CH) | 2017-11-02 | — | — | US | disclosed |
| US-20170304163-A1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | GIVAUDAN S.A. (CH) | 2017-10-26 | — | — | US | disclosed |
| US-20130133679-A1 | COSMETIC TREATMENT PROCESS USING A COATING BASED ON A COPOLYMER CONTAINING POLYAMIDE BLOCKS AND POLYETHER BLOCKS | L'OREAL (FR) | 2013-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130133679-A1 | COSMETIC TREATMENT PROCESS USING A COATING BASED ON A COPOLYMER CONTAINING POLYAMIDE BLOCKS AND POLYETHER BLOCKS | KRT18, CUTA, TPRKB | KMT2A 196/4885MAPT 385/4885MEN1 2950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.